Physician profile
Vera Grant
NPI 1487201018
$1,859.16
in general payments reported to CMS, 2019-2025
12 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $270 · 2023: $649 · 2024: $330 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.84 | 2021-2024 | |
| Gilead Sciences, INC. | $318.28 | 2021-2023 | Epclusa |
| Janssen Scientific Affairs, LLC | $126.86 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Ardelyx, INC. | $124.72 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $100.73 | 2025 | Rezdiffra |
| Organon LLC | $66.17 | 2023-2024 | Hadlima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.27 | 2023-2024 | Trulance |
| Merck Sharp & Dohme LLC | $24.78 | 2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $18.21 | 2023 | Ocaliva |
| Celgene Corporation | $15.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.89 | 2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.